IV Iron Supplementation Should Be Withheld When Transferrin Saturation ≥ 50 % in CKD Patients
Iron Parameter Thresholds
- A transferrin saturation (TSAT) ≥ 50 % indicates that additional intravenous (IV) iron is unlikely to improve hemoglobin or reduce erythropoiesis‑stimulating agent (ESA) dose and may increase the risk of iron overload. NKF‑K/DOQI recommends withholding IV iron above this threshold. 1, 2
- The target TSAT range for CKD patients is ≥ 20 % and ≤ 50 %; values above 50 % exceed the upper safety limit. 1, 2
- Ferritin levels ≥ 100 ng/mL satisfy the minimum target for iron stores; values above this do not mandate further supplementation. 3, 4, 5
Hemoglobin Target Considerations
- The recommended hemoglobin (Hb) target for CKD patients on ESA therapy is 11–12 g/dL (≈ 33–36 % hematocrit). Maintaining Hb above 12 g/dL requires specific clinical justification. 3, 4, 5
Management Recommendations
- Hold all IV iron and re‑evaluate iron indices every 3 months as per NKF‑K/DOQI monitoring guidance. 6, 2
- Continue the current ESA dose (e.g., 4000 IU weekly) without concurrent iron supplementation when TSAT is ≥ 50 % and ferritin is ≥ 100 ng/mL. 3, 4, 1
- Re‑check TSAT and ferritin at the 3‑month interval to ensure values remain within target ranges. 6, 2
- If Hb rises above 12.5 g/dL, consider reducing the ESA dose to keep the patient within the recommended Hb window. 3, 4
- Resume IV iron only when TSAT falls below 20 % or ferritin drops below 100 ng/mL, indicating a true iron deficiency. 4, 5, 1
Pitfalls to Avoid
- Do not initiate IV iron solely because the patient is on hemodialysis; iron therapy must be guided by TSAT and ferritin, not dialysis status alone. 3, 4
- Avoid the misconception that all dialysis patients require continuous IV iron; supplementation should be titrated to maintain TSAT ≥ 20 % and ferritin ≥ 100 ng/mL. 4, 5, 6